An ally to find our voice

Hôpitaux Robert Schuman and the Luxembourg Institute of Health (LIH) join forces on Colive Voice study

• Department of Precision Health
• Deep Digital Phenotyping Research Unit
• Colive Voice
• Cancer
• Digital Health
• Precision Health

Hôpitaux Robert Schuman has agreed to become a partner in the Colive Voice study, led by the Deep Digital Phenotyping research unit of the LIH Department of Precision Health (DoPH). This digital health study leverages developments in artificial intelligence to advance the diagnosis, risk prediction and remote monitoring of various chronic conditions (cancer, diabetes, covid-19, inflammatory bowel diseases, mental health issues…) by evaluating voice features.

Convinced by the innovative aspect of this LIH project which opens the way to new medical technologies, in particular voice monitoring of chronic diseases, Hôpitaux Robert Schuman has agreed to help recruit participants. From January 2022 onwards, brochures and flyers about the study will be made available to patients in cancer and diabetes consultations. Patients will be able to participate directly from their smartphone, computer or tablet by accessing the Colive Voice web application, by answering an online questionnaire and recording their voice.

In addition to providing support for the recruitment of participants, researchers from Colive Voice and from the Hôpitaux Robert Schuman’s Clinical Research Unit will collaborate on the analysis of the study results and on the publications that will result from them.

The partnership will allow a better representation of Luxembourgish citizens in this international research effort. Researchers hope that the voice technologies based on the study’s results could one day be used in telemedicine, remote monitoring of patients between clinical visits, or to evaluate the effectiveness of a drug in a clinical trial.

ABOUT HÔPITAUX ROBERT SCHUMAN  

Hôpitaux Robert Schuman were created in 2014 from the merger of the Bohler Clinic, the Kirchberg Hospital, the ZithaKlinik located in Luxembourg City and the Sainte Marie Clinic located in Esch-sur-Alzette: 306 doctors under private practice status and more than 2,200 employees are committed to providing high quality care and a personalized service with a strong human component.

The Group’s mission is to care for patients at all stages of their treatment – preventive, curative or palliative, but also to raise awareness and transfer knowledge through patient education and training for all hospital professionals.

HRS-Group core business is to coordinate and provide complex, high-tech, high-risk and high-cost medical care. Together with its partners, the HRS-group transforms hospital care into shorter, safe stays with high added value for patients and employees. This transformation is based on : efficient work organization, digitalisation, research and capitalizing on the human experience.

The Group’s clearly defined missions are structured around seven centers of expertise: the Women, Mother and Child center, the Internal Medicine center, the Locomotor System center, the Psychiatry center, the Visceral-Oncology center and the Geriatric center. The Robert Schuman Hospitals have a modern structure to meet the expectations of health professionals and ensure the best possible care for its patients. Academic and research roles complete the missions of the divisions.

ABOUT THE LUXEMBOURG INSTITUTE OF HEALTH (LIH)

The Luxembourg Institute of Health (LIH) is a public biomedical research organization focused on precision health and invested in becoming a leading reference in Europe for the translation of scientific excellence into meaningful benefits for patients.

LIH places the patient at the heart of all its activities, driven by a collective obligation towards society to use knowledge and technology arising from research on patient derived data to have a direct impact on people’s health. Its dedicated teams of multidisciplinary researchers strive for excellence, generating relevant knowledge linked to immune related diseases and cancer.

The institute embraces collaborations, disruptive technology and process innovation as unique opportunities to improve the application of diagnostics and therapeutics with the long-term goal of preventing disease.